The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2019

Filed:

Jan. 27, 2017
Applicant:

The Industry & Academic Cooperation IN Chungnam National University (Iac), Daejeon, KR;

Inventors:

Eunhee Kim, Daejeon, KR;

Sung-Eun Yoo, Sejong-si, KR;

Nam Sook Kang, Daejeon, KR;

Tae-Sung Koo, Daejeon, KR;

Min-Young Park, Daejeon, KR;

Young-Hoon Kim, Gyeonggi-do, KR;

Hyun-Ju Bae, Gyeonggi-do, KR;

Jin-Woo Kim, Gyeonggi-do, KR;

Tae-Kyu In, Chungcheongnam-do, KR;

Choun-Ki Joo, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/4353 (2006.01); C07D 495/04 (2006.01); C07D 413/06 (2006.01); A23L 33/16 (2016.01); A23L 33/00 (2016.01); C07D 209/42 (2006.01); C07D 235/24 (2006.01); C07D 307/85 (2006.01); C07D 333/58 (2006.01); C07D 333/60 (2006.01); C07D 333/74 (2006.01); C07D 409/04 (2006.01); C07D 409/06 (2006.01);
U.S. Cl.
CPC ...
C07D 495/04 (2013.01); A23L 33/16 (2016.08); A23L 33/40 (2016.08); C07D 209/42 (2013.01); C07D 235/24 (2013.01); C07D 307/85 (2013.01); C07D 333/58 (2013.01); C07D 333/60 (2013.01); C07D 333/74 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 413/06 (2013.01); A23V 2002/00 (2013.01);
Abstract

The present invention relates to a novel indene derivative, a preparation method for the same, and a pharmaceutical composition for treating retinal disease comprising the same as an active ingredient. The novel indene derivative of the present invention, the optional isomer of the same, or the pharmaceutically acceptable salts of the same have excellent inhibitory efficiency of receptor-interacting serine-threonine-protein kinase 1 (RIPK1). Therefore, the composition containing the same as an active ingredient can be effectively used as a pharmaceutical composition for treating retinal disease.


Find Patent Forward Citations

Loading…